Announced details
More than 140 companies have been designated as OASES strategic enterprise partners since the program began in October 2022
Strategic partnership. ROHTO Pharmaceutical Co., Ltd. signed an agreement to become a strategic enterprise partner.
A Hong Kong Government agency that operates a strategic enterprise partner program providing tailored support for companies entering or expanding their businesses in Hong Kong, with the aim of developing Hong Kong as a hub for innovation, research and development, and business in Asia. More than 140 companies have been designated since the program began in October 2022.
Building 15W, Phase 3, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Hong Kong Government OASES
| Item | Details |
|---|---|
| Names of Products / Services Covered | Eye care products, Skin care products, Regenerative medicine business, Next-generation pharmaceuticals, medical devices and treatments |
| Counterparty | Hong Kong Government Office for Attracting Strategic Enterprises (OASES) |
| Counterparty overview | A Hong Kong Government agency that operates a strategic enterprise partner program providing tailored support for companies entering or expanding their businesses in Hong Kong, with the aim of developing Hong Kong as a hub for innovation, research and development, and business in Asia. More than 140 companies have been designated since the program began in October 2022. |
| Relationship with the Company | Strategic partnership. ROHTO Pharmaceutical Co., Ltd. signed an agreement to become a strategic enterprise partner. |
| Contract Date | 23 October 2026 |
| Applicable area | Healthcare, Medical, Regenerative Medicine, Ophthalmology, Dermatology, Orthopedics, Medical devices |
| Location | Building 15W, Phase 3, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong |
| Usage history | More than 140 companies have been designated as OASES strategic enterprise partners since the program began in October 2022 |
| Source | Hong Kong Government OASES |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company was recognized for its expertise and business track record in the healthcare and medical fields, as well as its efforts to create value over the medium to long term in Asia, including Hong Kong.